DBF4B

Across TCGA pan-cancer cohorts, DBF4B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DBF4B data layer compared with 29 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher DBF4B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated DBF4B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, KIRP, and PRAD are the cancer types where DBF4B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.933	0.432	.012	28	view →
KIRP	OS	Median	III,IV	0.236	0.809	<.001	12	view →
PRAD	DFS	Median	All	0.106	0.774	<.001	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DBF4B–UCEC (DFS)

Open the UCEC breakdown →